NAD+ (nicotinamide adenine dinucleotide) is an essential cellular coenzyme required for mitochondrial energy production, DNA repair, and metabolic signaling. Tissue levels decline with age and metabolic stress. Clinically conservative, biomarker-guided protocols. Not anti-aging marketing — supportive cellular metabolism work.
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme present in every living cell. It is not a peptide in the strict sense — we include it on the peptide page because it is administered through similar injectable protocols and shares the same clinical-monitoring framework. NAD+ is a dinucleotide composed of nicotinamide and adenine, and it acts as a substrate or cofactor in hundreds of cellular reactions.
Its central biological roles are well established:
Tissue NAD+ levels decline with age and in states of chronic metabolic stress. That decline is well documented in the basic-science literature. What is less settled is the degree to which exogenous NAD+ administration translates into specific, measurable clinical outcomes. We discuss that evidence frontier with patients before any prescription.
The biology of NAD+ as a coenzyme is well established. Clinical trial evidence for direct exogenous NAD+ administration translating into specific clinical outcomes is more limited and continues to emerge. Oral precursors (nicotinamide riboside / NR, nicotinamide mononucleotide / NMN) have more clinical data than direct injectable NAD+. Compounded injectable NAD+ is not FDA approved for any specific indication. We are transparent with every NAD+ candidate about what is well-supported versus investigational.
NAD+ supplementation at THE WELLNESS CO. is most often used as a supportive layer in patients with documented metabolic decline, fatigue patterns supported by baseline labs, or as part of a recovery-focused protocol. Specifically:
What it isn't. NAD+ is not an anti-aging drug, a longevity guarantee, a cure for neurodegenerative disease, or a substitute for addressing underlying hormonal, sleep, or metabolic drivers of fatigue. We do not market it that way. We do not prescribe it that way.
NAD+ candidates undergo the standard CLARITY methodology baseline: 42-marker panel with particular attention to thyroid function, fasting insulin, HbA1c, hormone panel, B-vitamin status, and inflammatory markers. The reason: most fatigue presentations have addressable upstream drivers that NAD+ alone will not resolve.
A patient with suppressed thyroid, declining hormones, low B12, or unaddressed insulin resistance often benefits more from correcting those drivers than from layering NAD+ on top. NAD+ may enter the protocol later as a supportive cellular layer once those upstream factors are addressed — or it may be combined with them if the clinical picture supports both.
Smaller doses on a defined cadence (commonly daily or several times weekly during an induction phase; less frequent during maintenance). Most patients tolerate these injections well — the experience is similar to other injectable peptide protocols. This is the most common form we administer.
Larger single-session doses. IV NAD+ must be infused slowly (commonly over two to four hours) because rapid infusion reliably produces flushing, chest pressure, and GI discomfort. Adequate hydration before and during infusion improves tolerability. Patients should expect a long appointment and to feel some warmth or pressure sensations during the session. IV NAD+ is not the right format for patients who cannot tolerate the infusion experience.
Adequate hydration is important for both injection and IV forms. We discuss expectations and side effects before any session, particularly for first IV infusions.
There is no specific clinical assay for tissue NAD+ levels that we routinely use. Monitoring is primarily clinical:
Patients with active malignancy. NAD+ is required for cellular metabolism in both healthy and malignant cells, and theoretical concerns regarding NAD+ availability in cancer biology have not been fully resolved; in the absence of clear safety data, we do not prescribe to active-cancer patients. Pregnant or breastfeeding patients. Patients with significant cardiovascular disease should be evaluated carefully, especially for IV infusion. Patients with severe hepatic or renal impairment require dose adjustment or alternative approach. Patients seeking NAD+ as a stand-alone anti-aging or cognitive-enhancement intervention without supporting clinical context are not appropriate candidates — we look for a clinical reason first.
NAD+ is rarely the right standalone intervention. The most common combinations:
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It is required for mitochondrial energy production (the electron transport chain), DNA damage repair (the PARP pathway), and the activity of sirtuin deacetylases that regulate cellular metabolism and stress response. NAD+ levels naturally decline with age, and lower tissue levels have been correlated with markers of metabolic and mitochondrial decline. NAD+ supplementation aims to support those tissue levels — though the strength of the clinical evidence linking exogenous NAD+ to specific outcomes varies by indication.
Subcutaneous and intramuscular NAD+ injections deliver smaller doses on a recurring cadence and are typically more comfortable to receive — most patients tolerate them well. Intravenous NAD+ delivers larger doses in a single session but must be infused slowly (commonly over 2-4 hours) because rapid infusion produces flushing, chest pressure, and GI discomfort. The two routes are appropriate for different clinical contexts; the choice is individualized.
The biology of NAD+ as a coenzyme is well established. Clinical trial evidence for direct NAD+ administration (vs. oral precursors like nicotinamide riboside or nicotinamide mononucleotide) is more limited and continues to emerge. We are transparent with patients about which claims are well-supported (NAD+'s biological role, age-related decline) and which remain investigational (direct outcomes from exogenous administration). Compounded injectable NAD+ is not FDA approved for any specific indication.
Subcutaneous/intramuscular injections typically produce minimal sensation beyond the injection itself. IV NAD+ infusion is commonly accompanied by flushing, a sensation of chest pressure, and occasional nausea during the infusion — these are dose- and rate-dependent and usually resolve when the infusion rate is slowed. Adequate hydration improves tolerability. Patients may also experience transient fatigue or anxiety in the hours after administration.
Patients with active malignancy. NAD+ is required for cellular metabolism in both healthy and malignant cells, and the theoretical concerns regarding NAD+ availability in cancer biology have not been fully resolved; in the absence of clear safety data, we do not prescribe to active-cancer patients. Pregnant or breastfeeding patients. Patients with significant cardiovascular disease should be evaluated carefully (especially for IV infusion). Patients with severe hepatic or renal impairment require dose adjustment or alternative approach.
Upload existing bloodwork. Our clinical team reads it through the CLARITY framework to identify whether NAD+ is the right next layer or whether upstream drivers should be addressed first. Free.
Get Your Free Lab Review →One consultation. Your biomarkers map the protocol.
Book Your Consultation